0.003% AR-15512 ophthalmic solution

DRUG6 trials

Sponsors

Aerie Pharmaceuticals, Alcon Research

Conditions

Dry Eye Disease

Phase 3

Study Evaluating the Safety and Efficacy of AR-15512

CompletedNCT05285644

Aerie PharmaceuticalsDry Eye Disease

Start: 2022-05-09End: 2023-07-24Updated: 2025-07-23

Study Evaluating the Safety and Efficacy of AR-15512 (COMET-3)

CompletedNCT05360966

Aerie PharmaceuticalsDry Eye Disease

Start: 2022-07-18End: 2023-10-17Updated: 2025-07-23

A Long-Term Safety Study Evaluating the Safety and Systemic Exposure of AR-15512

CompletedNCT05493111

Aerie PharmaceuticalsDry Eye Disease

Start: 2022-11-01End: 2024-02-28Updated: 2025-08-13

A Study Designed to Evaluate Tear Production

CompletedNCT06544707

Alcon ResearchDry Eye Disease

Start: 2024-10-15End: 2025-01-30Updated: 2026-02-10

A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease

CompletedNCT06544694

Alcon ResearchDry Eye Disease

Start: 2024-10-08End: 2025-03-21Updated: 2026-03-27

A Study to Evaluate 0.003% AR-15512 Safety and Drop Attributes

CompletedNCT06660290

Alcon ResearchDry Eye Disease

Start: 2025-01-15End: 2025-02-06Updated: 2026-03-17

Related Papers

Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies.

2025-09-30